Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)
This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.
Authors
- Wojciech Michalak (ORCID: https://orcid.org/0000-0002-3390-0182)
- Mads Faurby (ORCID: https://orcid.org/0000-0001-6464-9958)
- Angela Fitch (ORCID: https://orcid.org/0000-0001-9912-5994)
- Zhenxiang Zhao
- Sara Álvarez (ORCID: https://orcid.org/0009-0002-6804-6470)
Institutions
- Know Center Research GmbH (Austria) (AT)
- Academic Rights Press (United Kingdom) (GB)
- Novo Nordisk (United States) (US)
- Novo Nordisk (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1080/13696998.2025.2526282
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59